Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about RGEN, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Secretin Human (RG1068) | Pancreatitis | Phase 3 · NCT00660335 | Completed |
| Uridine | Bipolar I Depression | Phase 2 · NCT00812058 | Completed |
| Secretin | Schizophrenia | Phase 2 · NCT00235274 | Completed |
| Uridine Triacetate (RG2133) | Mitochondrial Diseases | Phase 1 · NCT00060515 | Terminated |
| Secretin Synthetic Human (RG1068) | Pancreas Cancer | Early Phase 1 · NCT01371240 | Withdrawn |
Also used in these trials (approved or third-party drugs, not RGEN's own candidates): Abatacept (RG2077).
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
RGEN holds $863M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 7 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when RGEN files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| FMR LLC | Institution (13G, 5%+) | 7,361,318 | 11.52% | 2026-09-30 |
| Vanguard Capital Management | Institution (13G, 5%+) | 2,825,579 | 4.42% | 2026-06-30 |
| Karen A Dawes Director · +2,239 options |
Insider | 92,816 | 0.15% | 2026-05-14 |
| Anthony Hunt Director |
Insider | 89,062 | 0.14% | 2026-03-02 |
| Olivier Loeillot Chief Executive Officer, Director · +48,806 options |
Insider | 45,788 | 0.07% | 2026-10-05 |
| Glenn P Muir Director · +4,673 options |
Insider | 40,051 | 0.06% | 2026-05-14 |
| James Bylund Chief Operating Officer · +8,315 options |
Insider | 25,423 | 0.04% | 2026-03-05 |
| Ralf Kuriyel Senior VP, R&D · +5,669 options |
Insider | 20,062 | 0.03% | 2026-03-05 |
| Jason K Garland CFO · +8,315 options |
Insider | 18,408 | 0.03% | 2026-09-25 |
| Brian Robb Douglass CHIEF PRODUCT OFFICER · +2,818 options |
Insider | 8,685 | 0.01% | 2026-10-06 |
| Martin D Madaus Director · +2,239 options |
Insider | 8,392 | 0.01% | 2026-05-14 |
| Violetta Hughes CHIEF ACCOUNTING OFFICER |
Insider | 6,331 | 0.01% | 2026-03-05 |
Share count 63,923,738 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RGEN and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →